{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:01:47Z","timestamp":1792404107507,"version":"4.4.0"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T00:00:00Z","timestamp":1280275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The aim of this study was to develop and validate a novel bioassay for determining serum voriconazole (VRC) concentrations and to compare its routine clinical performance with that of high\u2010performance liquid chromatography (HPLC). The biological activity of VRC was measured by a plate diffusion assay using a VRC\u2010hypersusceptible <jats:italic>Candida kefyr<\/jats:italic> strain. The bioassay\u2019s utility was tested by measuring steady\u2010state VRC concentrations in 100 serum probes from VRC\u2010treated patients. The HPLC system used solvent extraction with hexane\u2003:\u2003dichloromethane followed by reversed\u2010phase HPLC with ultraviolet detection. The intra\u2010day and inter\u2010day accuracy of the bioassay was &lt;5%, while that of HPLC was &lt;1%. The precision (mean coefficient of variation, 3.5%) was equal for both the methods. The limit of quantification was lower for HPLC (0.2\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup>) than for the bioassay (0.5\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup>). The result of linear regression analysis was HPLC\u2003=\u20031.0178 (bioassay)\u2003+\u20030.328; <jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2003=\u20030.88; <jats:italic>n<\/jats:italic>\u2003=\u2003100. Results of the serum panel ranged from 0.5 to more than 8.0\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for the bioassay and from 0.26 to 10.1\u2003mg\u2003l<jats:sup>\u22121<\/jats:sup> for HPLC. Especially in laboratories without access to HPLC, the bioassay may be a clinically useful tool for therapeutic drug monitoring.<\/jats:p>","DOI":"10.1111\/j.1439-0507.2010.01938.x","type":"journal-article","created":{"date-parts":[[2010,7,28]],"date-time":"2010-07-28T10:24:12Z","timestamp":1280312652000},"source":"Crossref","is-referenced-by-count":13,"title":["Comparison and evaluation of a novel bioassay and high\u2010performance liquid chromatography for the clinical measurement of serum voriconazole concentrations"],"prefix":"10.1111","volume":"54","author":[{"given":"Joerg","family":"Steinmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Huelsewede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Buer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter\u2010Michael","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,13]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2002.t01-2-02002.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/313749"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2166-2172.2004"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03315.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02000.x"},{"key":"e_1_2_5_10_2","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof A","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_5_11_2","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"20","author":"Miyakis S","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/524669"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00957-06"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1209-1213.2000"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200412000-00011"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(96)00408-2"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.01.021"},{"key":"e_1_2_5_18_2","unstructured":"Guidance for Industry.Bioanalytical Method Validation. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM) 2001. URLhttp:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf[accessed on 1 December 2009]."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31817b1a95"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L243"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2008.01660.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01316-08"},{"key":"e_1_2_5_23_2","article-title":"Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients","volume":"3","author":"R\u00fcping MJ","year":"2009","journal-title":"Mycoses"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1878-1880.2006"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2010.01938.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1439-0507.2010.01938.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:06:44Z","timestamp":1697256404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2010.01938.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1439-0507.2010.01938.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2010.01938.x","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}